Sector analysis · India
Healthcare sector earnings growth, Q4 FY24
The 20 largest Healthcare companies by market cap at the end of Q4 FY24 (31 Mar 2024), compared with Q3 FY24.
The top 20 at Q4 FY24
Q4 FY24 vs Q3 FY24: combined net profit ₹9,619 cr (−9%), median EPS −1% (9 of 18 up), market-cap-weighted price +14%. 20 of 20 reported.
| # | Company | Weight | EPS ₹, base → now | EPS growth | Contribution | Price |
|---|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited | 23.5% | 10.52 → 11.06 | +5% | +1.2 pp | +29% |
| 2 | Cipla Limited | 7.3% | 13.08 → 11.63 | −11% | −1.1 pp | +20% |
| 3 | Dr. Reddy's Laboratories Limited | 6.2% | 16.56 → 15.70 | −5% | −0.7 pp | +6% |
| 4 | Zydus Lifesciences Limited | 6.2% | — → 0.63 | sources disagree | — | +46% |
| 5 | Mankind Pharma Limited | 5.6% | 11.33 → 11.76 | +4% | +0.2 pp | +16% |
| 6 | Divi's Laboratories Limited | 5.5% | 13.49 → 20.27 | +50% | +1.7 pp | −12% |
| 7 | Apollo Hospitals Enterprise Limited | 5.5% | 17.06 → 17.65 | +3% | +0.1 pp | +11% |
| 8 | Torrent Pharmaceuticals Limited | 5.3% | 13.09 → 13.27 | +1% | +0.1 pp | +13% |
| 9 | Max Healthcare Institute Limited | 4.8% | 2.98 → 2.58 | −13% | −0.4 pp | +19% |
| 10 | Lupin Limited | 4.5% | 13.47 → 7.89 | −41% | −2.4 pp | +22% |
| 11 | Aurobindo Pharma Limited | 3.9% | 15.98 → 15.51 | −3% | −0.3 pp | 0% |
| 12 | Alkem Lab | 3.6% | 49.76 → 24.55 | −51% | −2.9 pp | −5% |
| 13 | Abbott India Limited | 3.5% | 146.35 → 135.09 | −8% | −0.2 pp | +19% |
| 14 | Accent Microcell | 2.8% | — → 6.70 | — one source | — | +13% |
| 15 | Global Health Limited | 2.1% | 4.61 → 4.74 | +3% | 0.0 pp | +38% |
| 16 | GlaxoSmithKline Pharmaceuticals Limited | 2.0% | 2.70 → 11.48 | +325% | +1.4 pp | +3% |
| 17 | Fortis Healthcare Limited | 1.9% | 1.78 → 2.37 | +33% | +0.4 pp | 0% |
| 18 | Biocon Limited | 1.9% | 5.50 → 1.13 | −79% | −5.0 pp | +6% |
| 19 | IPCA Laboratories Limited | 1.9% | 7.09 → 2.35 | −67% one-off | −1.1 pp | +11% |
| 20 | Gland Pharma Limited | 1.8% | 11.65 → 11.68 | 0% | 0.0 pp | −4% |
| Sector earnings growth | 100% | −8.9 pp |
Who joined and who left
1 joined and 1 left the top 20 since Q3 FY24, as market caps moved.
Joined the top 20 since Q3 FY24
Left the top 20 since Q3 FY24
- Syngene International Limited
EPS growth by company, Q2 FY24 to Q1 FY27
Each company's EPS growth quarter on quarter, every quarter it was in the top 20.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | +17% | +6% | +5% | +7% | +7% | −4% | −26% | +6% | +37% | +8% | −19% | +7% |
| CIPLA | +14% | −7% | −11% | +25% | +11% | +21% | −22% | +6% | +4% | −50% | −18% | +42% |
| DRREDDY | +5% | −7% | −5% | +6% | −10% | +13% | +13% | −11% | −5% | −10% | −82% | +101% |
| ZYDUSLIFE | −26% | −1% | sources disagree | sources disagree | −36% | +12% | sources disagree | sources disagree | −14% | −17% | +22% | −26% |
| MANKIND | +1% | −9% | +4% | +14% | +22% | −43% | +11% | +4% | +17% | −20% | +36% | +3% |
| DIVISLAB | −2% | +3% | +50% | −20% | +19% | +16% | +12% | −18% | +26% | −15% | +29% | +20% |
| APOLLOHOSP | +40% | +5% | +3% | +20% | +24% | −2% | +5% | +11% | +10% | +5% | +5% | +10% |
| TORNTPHARM | +2% | +15% | +1% | +2% | −1% | +11% | −1% | +10% | +8% | +7% | −39% | +46% |
| MAXHEALTH | +15% | +5% | −13% | −6% | +19% | −15% | +33% | −3% | +59% | −39% | +14% | −6% |
| LUPIN | +8% | +25% | −41% | +123% | +6% | 0% | −10% | +58% | +21% | −20% | +24% | −3% |
| AUROPHARMA | +33% | +24% | −3% | +1% | −10% | +3% | +7% | −9% | +3% | +7% | +1% | +13% |
| ALKEM | +116% | −4% | −51% | +86% | +26% | −9% | −51% | +117% | +15% | −17% | −63% | +120% |
| ABBOTINDIA | +8% | −1% | −8% | +14% | +9% | +1% | +2% | 0% | +14% | −9% | +5% | +9% |
| ACCENTMIC | — | — | — | — | — | — | — | outside | outside | outside | outside | outside |
| MEDANTA | outside | outside | +3% | −16% | outside | outside | outside | outside | outside | outside | outside | outside |
| GLAXO | +64% | −79% | +325% | −6% | +39% | −9% | +14% | −22% | +26% | +15% | −6% | outside |
| FORTIS | +55% | −23% | +33% | −7% | +6% | +41% | −26% | +41% | +23% | −40% | +37% | 0% |
| BIOCON | +25% | +424% | −79% | +386% | to loss | turned profitable | +1,267% | sources disagree | sources disagree | sources disagree | sources disagree | sources disagree |
| IPCALAB | outside | +24% | −67% | outside | +19% | +8% | −73% | outside | outside | outside | −8% | +34% |
| GLAND | 0% | −1% | 0% | −25% | outside | outside | outside | outside | outside | outside | outside | outside |